Roche will acquire Adheron Therapeutics in a deal worth up to $580 million, according to a Reuters article.
Adheron, a California-based biotech, offers technology that disrupts immune cell adhesion through a protein called Cadherin-11. Its lead asset, SDP051, is a humanized monoclonal antibody that has completed Phase 1 of clinical development.
Adheron's shareholders will get $105 million in cash, plus up to $475 million in potential milestones. Read the full story
